Biomedical products

Data

Feature

Request Demo

Last update 01 Nov 2024

Dysautonomia Like Disorder

Last update 01 Nov 2024

Basic Info

Synonyms

DYSAUTONOMIA-LIKE DISORDER, Dysautonomia like disorder, Dysautonomia-Like Disorder

+ [1]

Introduction-

Drugs associated with Dysautonomia Like Disorder

Clotiazepam

Target

GABAA receptor

Mechanism

GABAA receptor agonists

Active Org.

Mitsubishi Tanabe Pharma Corp.

Originator Org.

Mitsubishi Tanabe Pharma Corp.

Active Indication

Anxiety Disorders [+3]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date31 May 1988

Tofisopam

Target

GABAA receptor

Mechanism

GABAA receptor agonists

Active Org.

Mochida Pharmaceutical Co., Ltd.

Originator Org.-

Active Indication

Dysautonomia Like Disorder [+1]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date05 Nov 1985

Clinical Trials associated with Dysautonomia Like Disorder

NCT05638620 / Active, not recruitingPhase 1IIT

Evaluating the Effectiveness of Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Post-Acute Sequelae of SARS-CoV-2 (PASC)

The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.

Start Date03 Jan 2023

Sponsor / Collaborator

Hudson Medical

100 Clinical Results associated with Dysautonomia Like Disorder

100 Translational Medicine associated with Dysautonomia Like Disorder

0 Patents (Medical) associated with Dysautonomia Like Disorder

Literatures (Medical) associated with Dysautonomia Like Disorder

01 Jan 1976·European NeurologyQ4 · MEDICINE

A Case of New Dysautonomia-Like Disorder Found in Japan

Q4 · MEDICINE

Article

Author: Fujii, K. ; Oura, T. ; Hayashi, A. ; Higa, S. ; Sato, Y. ; Nakagawa, T. ; Suzuki, T.

A case of new dysautonomia-like disorder in a Japanese infant is reported. The patient showed almost all of the essential criteria for the diagnosis of familial dysautonomia. Results of pharmacologic tests and urinary excretion patterns of catecholamines and their metabolites were also compatible with the disorder. But he lacked some important clinical findings, such as lifelong hypolacrimia, skin blotching, excessive sweating and labile blood pressure. Precise observations of clinical features and literatures on non-Jewish cases of familial dysautonomia lent evidence that this case suffered from a new dysautonomia-like disorder.

Human Genome Variation

The case of a patient with MIRAGE syndrome with familial dysautonomia-like symptoms

Article

Author: Tanase-Nakao, Kanako ; Namba, Noriyuki ; Kawashima-Sonoyama, Yuki ; Dohmoto, Tomotsune ; Okuno, Keisuke ; Narumi, Satoshi

AbstractWe describe a case of posthumously diagnosed MIRAGE syndrome (Myelodysplasia, Infection, Restriction of growth, Adrenal hypoplasia, Genital problems, and Enteropathy) in a girl with a new pathogenic SAMD9 variant (p.F437S), who was initially considered to have familial dysautonomia (FD)-like disease due to increased levels of catecholamine metabolites. Functional analyses of F437S-SAMD9 were performed, showing characteristics of disease-causing variants. This new SAMD9 variant (p.F437S) also causes MIRAGE syndrome.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Who we are

Solutions
Plan
Contact us

What we do

Drug
Clinical Progress
Patent
Literature
Report
News

Dysautonomia Like Disorder

Basic Info

Related

Analysis